bs-10014R Search Results


v2r  (Bioss)
94
Bioss v2r
ZWD inhibits renal MR and <t>V2R</t> expression in NS. (A) Protein levels of MR and V2R detected by WB ( n = 6). (B–C) mRNA levels of MR and V2R detected by RT-qPCR ( n = 6). Model group vs. control group (** p < 0.01, ANOVA followed by LSD); ZWD and prednisone groups vs. model group (# p < 0.05, ## p < 0.01, ANOVA followed by LSD). V2R: type 2 <t>vasopressin</t> <t>receptor;</t> MR: mineralocorticoid receptor; ZWD: Zhenwu Decoction; LSD: least significant difference; WB: western blot.
V2r, supplied by Bioss, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/v2r/product/Bioss
Average 94 stars, based on 1 article reviews
v2r - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier

Image Search Results


ZWD inhibits renal MR and V2R expression in NS. (A) Protein levels of MR and V2R detected by WB ( n = 6). (B–C) mRNA levels of MR and V2R detected by RT-qPCR ( n = 6). Model group vs. control group (** p < 0.01, ANOVA followed by LSD); ZWD and prednisone groups vs. model group (# p < 0.05, ## p < 0.01, ANOVA followed by LSD). V2R: type 2 vasopressin receptor; MR: mineralocorticoid receptor; ZWD: Zhenwu Decoction; LSD: least significant difference; WB: western blot.

Journal: Renal Failure

Article Title: Zhenwu decoction ameliorates adriamycin-induced nephrotic syndrome in rats via dual modulation of AVP-V2R-AQP2 and RAAS-MR-AQP3 pathways

doi: 10.1080/0886022X.2025.2599570

Figure Lengend Snippet: ZWD inhibits renal MR and V2R expression in NS. (A) Protein levels of MR and V2R detected by WB ( n = 6). (B–C) mRNA levels of MR and V2R detected by RT-qPCR ( n = 6). Model group vs. control group (** p < 0.01, ANOVA followed by LSD); ZWD and prednisone groups vs. model group (# p < 0.05, ## p < 0.01, ANOVA followed by LSD). V2R: type 2 vasopressin receptor; MR: mineralocorticoid receptor; ZWD: Zhenwu Decoction; LSD: least significant difference; WB: western blot.

Article Snippet: The primary antibodies used were against MR (diluted 1:500, BS-1850R, BIOSS), V2R (diluted 1:1000, BS-10014R, BIOSS), AQP1 (diluted 1:1000, AF5231, Affinity), AQP2 (diluted 1:2000, DF7560, Affinity), AQP3 (diluted 1:2000, BS-1253R, BIOSS), and β-actin (diluted 1:30000, 66009-1-Ig, Proteintech, USA).

Techniques: Expressing, Quantitative RT-PCR, Control, Western Blot

Compound–major target molecular docking analysis. (A) Initial 3D conformation of unoptimized bioactive compounds. (B) 3D conformation of optimized bioactive compounds. (C) Interaction mode of AQP1 with benzoylpaeoniflorin. (D–F) Interaction mode of AQP2, V2R, and MR with 6-gingerol. (G) Interaction mode of AQP3 with paeoniflorin. AQP: aquaporin; V2R: type 2 vasopressin receptor; MR: mineralocorticoid receptor.

Journal: Renal Failure

Article Title: Zhenwu decoction ameliorates adriamycin-induced nephrotic syndrome in rats via dual modulation of AVP-V2R-AQP2 and RAAS-MR-AQP3 pathways

doi: 10.1080/0886022X.2025.2599570

Figure Lengend Snippet: Compound–major target molecular docking analysis. (A) Initial 3D conformation of unoptimized bioactive compounds. (B) 3D conformation of optimized bioactive compounds. (C) Interaction mode of AQP1 with benzoylpaeoniflorin. (D–F) Interaction mode of AQP2, V2R, and MR with 6-gingerol. (G) Interaction mode of AQP3 with paeoniflorin. AQP: aquaporin; V2R: type 2 vasopressin receptor; MR: mineralocorticoid receptor.

Article Snippet: The primary antibodies used were against MR (diluted 1:500, BS-1850R, BIOSS), V2R (diluted 1:1000, BS-10014R, BIOSS), AQP1 (diluted 1:1000, AF5231, Affinity), AQP2 (diluted 1:2000, DF7560, Affinity), AQP3 (diluted 1:2000, BS-1253R, BIOSS), and β-actin (diluted 1:30000, 66009-1-Ig, Proteintech, USA).

Techniques: